FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline <i>BRCA</i>-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of ChemotherapyGeoffrey Kim, Richard Pazdur, Rajeshwari Sridhara et al.|Clinical Cancer Research|2015Cited by 526
Use of Nonconcurrent Common Control in Master Protocols in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum DiscussionRajeshwari Sridhara, Cindy Lu, Olga Marchenko et al.|Statistics in Biopharmaceutical Research|2021Cited by 35
Type I Error Considerations in Master Protocols With Common Control in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum DiscussionRajeshwari Sridhara, Bruce Binkowitz, Olga Marchenko et al.|Statistics in Biopharmaceutical Research|2021Cited by 12